Introduction
============

In 1890, Von Behring and Kitasato proved that serum from rabbits immunized with tetanus toxin had activity against the \"poison of tetanus\" and thus, when this serum was transferred to healthy rabbits, it protected them against tetanus.^([@R1])^ This was the first of many studies which showed that many diseases could be prevented or treated using the serum of both animals and humans.

At the beginning of World War II, Cohn and colleagues developed techniques that allowed the separation of plasma proteins in stable individual fractions, with different biological functions.^([@R2],[@R3])^ Such techniques were improved and are applied until now to prepare blood products. These techniques enable the preparation of human immunoglobulin (Ig).

In 1952, Ig began to be successfully used in patients with primary immunodeficiencies. However, intramuscular Ig caused some disadvantages, such as pain during infusion and a long time to reach peak serum levels.^([@R4])^ In 1960, the first Ig for intravenous use, prepared by the treatment of plasma with trypsin, was released. Since then, different laboratory strategies have been developed in order to obtain safer, effective and well tolerated blood products.

Ig was first used in the treatment of primary immunodeficiencies; indications for its use have increased greatly over the last 30 years. Therefore, Ig has become the primary or adjuvant treatment for various autoimmune and inflammatory diseases, due to its immunomodulatory and anti-inflammatory properties.

There were problems in the world\'s supply of Ig in the late 1990s when demand exceeded supplies by 30% and it was difficult to produce blood derivatives in Britain, a leading supplier of Ig. Moreover, there were increases in the number of well established clinical indications and in clinical indications that were not completely evidence based.^([@R5])^ In Brazil, the annual consumption is estimated at between 500 kg and 1 ton, the equivalent to 0.3 to 0.6 kg/100,000 inhabitants per year. To cater for this demand, Brazil imports more than 90% of human Ig.^([@R6])^

Methods of production and safety
================================

Ig is a sterile preparation of concentrated antibodies (immunoglobulins) that derive from large pools of human plasma from healthy donors. While the use of large plasma pools for the production of Ig provides a variety of antibodies, it increases the risk of infections, whether viral or prion. This fact has led to an unrelenting pursuit to raise security of Ig while maintaining the tolerability of this blood product.

Ig production begins with the selection of donors for plasma collection. One can deduce from this fact that Ig formulations are not equal, since they depend on the antibody composition of the donor population which varies depending on existent diseases in that population. A report was recently published that stated that antibody levels against hepatitis A were significantly different in various formulations of Ig.^([@R7])^

Plasma used for Ig production must come from healthy blood donors with known medical history and absence of known risk factors for blood-borne infectious diseases.^([@R8])^ Plasma may be collected by apheresis or come from a whole blood donation. It is not necessary to rapidly freeze plasma (less than 24 hours after collection) if it is only used for Ig and albumin production.

Plasma units collected should be negative for laboratory screening of human immunodeficiency virus (HIV) 1 and 2, and hepatitis viruses B and C. Serological methods and also molecular (NAT) methods should be used. In Brazil, plasma must also be negative for syphilis, Chagas\' disease and, in endemic areas, for malaria.

The Ig production process involves steps of fractionation and purification of plasma. There are two main techniques of plasma fractionation. The first one involves plasma precipitation by ethanol, used as a nontoxic precipitating agent, and the second is a chromatographic technique, which uses cylindrical columns containing synthetic resins that allow protein separation.^([@R9])^

Companies that manufacture blood products use different methods for the purification of plasma and several approved methods for viral removal and inactivation.^([@R10],[@R11])^ Currently, at least three techniques are being used to manufacture Ig in order to improve tolerability and reduce risks of disease transmission.

Each step in the processing of plasma may cause alterations in its protein structure and its biological activity. As a consequence, commercial preparations of Ig differ in tolerability, and they can also differ in efficacy.^([@R12])^ For example, some purification methods that include the addition of chemicals or enzymes, in order to inactivate viruses or to reduce the formation of aggregates of Ig, may also alter the structure and function of the Fc fragment of the IgG molecule and, consequently, decrease its biological activity.

The methods commonly used to reduce the viral load are: pasteurization, treatment with solvent/detergent, treatment with methylene blue, treatment with caprylic acid and nanofiltration. Of these, the caprylic acid and solvent/ detergent techniques are effective against enveloped viruses, while nanofiltration removes both enveloped viruses and non-enveloped viruses (parvovirus B19 and hepatitis A).^([@R13])^ There are formulations of Ig in which three methods are dedicated to the removal of pathogens: solvent/detergent treatment, 35-nm nanofiltration and incubation at low pH/high temperature to remove/inactivate viruses/ prions.^([@R14])^

Recently, it has been shown that methods of inactivation/removal of viruses, such as the use of nanofiltration and caprylate acid, protect the properties of Ig.^([@R12])^ It should be noted that not only the formulation of Ig should contain high levels of IgG (= 95%), but the molecule must also be intact and without aggregates. The presence of high concentrations of aggregates is correlated to reactions during the infusion of Ig.

In the 1980s, cases of viral transmission caused by Ig infusion were reported and created great concern among both the medical community and users as in many clinical situations there is no substitute for the blood product. However, since the solvent/detergent method and nucleic acid technology (NAT) have been added to the production process, no more cases of viral transmission were reported.^([@R15],[@R16])^

Mechanism of action
===================

In primary or secondary immunodeficiency, Ig administration has the aim of replacing antibodies and its mechanism of action is clearly defined: to restore the levels of IgG. However, considering the anti-inflammatory and immunomodulatory properties of Ig, several mechanisms have been suggested to elucidate the effects of this drug in the regulation of the immune system, some of which are shown in [Table 1](#T1){ref-type="table"}.^([@R17],[@R18])^ [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} explain graphically the main mechanisms of action of Ig.

###### 

Mechanisms of action of human immunoglobulin^([@R18])^

  -------------------------------------------------------------------------------------------------------------------
  Interaction with Fc fragment specific receptor (FcR)
  Control of complement pathways and activation of mechanisms inducing solubilization of circulating immune complex
  Formation of idiotype-anti-idiotype dimers
  Modulation of some cytokines and production of their antagonists
  Apoptosis of B and T cells through the activation of Fas receptor
  Blocking binding between T cells and superantigens
  Control of self reactivity and tolerance induction
  Inhibition of differentiation and maturation of dendritic cells
  -------------------------------------------------------------------------------------------------------------------

![Fc receptor blockade of phagocytes by Ig in a patient with immune thrombocytopenic purpura (presence of anti-platelet antibodies).](rbhh-33-377-g01){#F1}

![Multiple actions of Ig: formation of idiotype-anti-idiotype dimers, blocking the binding of superantigens to T cells, inhibition of dendritic cells, stimulation of Regulatory T cells (Tregs)](rbhh-33-377-g02){#F2}

Recently, the action of Ig on regulatory T cells (Tregs) of CD4^+^, CD25^+^ and FoxP3^+^ has been described. Tregs have a significant role in the maintenance of non-immune response to self antigens and prevention of immune aggression and autoimmune diseases.^([@R19])^ Ig has been shown to promote expansion and enhancement of the Treg suppressive function, but the mechanism is not known yet.^([@R20])^

Besides the relationship between IV Ig and Tregs, there is a hypothesis that there is an interaction between Ig and dendritic cells. These cells are antigen-presenting cells and are involved in the induction of immunogenic or tolerogenic immune response. It is believed that the effects of Ig on T cell activation may be mediated by dendritic cells.^([@R21])^

Recently, it was shown that Ig formulations have an inhibitory effect on the differentiation and amplification of TH17 cells. These cells correspond to a subpopulation of T cells that, besides protecting against extracellular pathogens (such as *Klebsiella* and *Candida*) play a critical role in the pathogenesis of various autoimmune, allergic and inflammatory diseases. Inhibition of TH17 cells reduces the production of a series of inflammatory cytokines and other pro-inflammatory mediators, thereby interfering in the maintenance of chronic inflammatory response.^([@R22])^

Formulations of human immunoglobulin
====================================

Ig preparations differ in stabilizers and diluents. Such variations make each product unique and, consequently, its effectiveness and tolerability are also specific. This explains, in part, why some patients have reactions to certain products and not to others.

Some characteristics of Ig formulations must be carefully observed. The first one is the presence of latex; 0.3 to 1% of the population is sensitive to this antigen and may have allergic reactions, sometimes severe, following exposure.^([@R23])^ The other one is the presence of sorbitol, which is contraindicated for patients with hereditary fructose intolerance. [Table 2](#T2){ref-type="table"} shows the main Ig formulations available in Brazil.

###### 

Formulations of human immunoglobulin available in Brazil^([@R24])^

  Product                                                             Formulation                               Presentation                                             Use     Excipient                                                                                 Latex     Origin
  ------------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------- ------- ----------------------------------------------------------------------------------------- --------- -------------------------------------------------------------------------------------
  Blauimuno ® (Blausiegel)                                            Lyophilized                               0.6,3, and 9.0 g                                         IV      Glucose, Sodium Chloride                                                                  No        CLB - Central Laboratory of the Netherlands
  Flebogamma 5% ® (Grifols Brasil)                                    Injectable solution                       0.5, 2.5, 5 and 10 g                                     IV      D-sorbitol, Water for injection                                                           No        Grifols Institute, Spain
  Gamaglobulina IM Grifols ® (Grifols Brasil)                         Injectable solution                       320 and 800 mg                                           IM      Glycine, sodium chloride, Water for injection                                             No        Grifols Institute, Spain
  Gamunex ® (Meizler Biopharma) Imunoglobulin® (Blausiegel)           Injectable solution Injectable solution   1,2.5, 5, 10 and 20 g 0.5, 1, 2.5, 3, 5 and 10 g         IV IV   N/D Maltose 100 mg/mL                                                                     N/D N/D   Talecris Biotherapeutics, INC (United States) Greencross Plasma Derivatives - Korea
  Imunoglobulin® (Blausiegel)                                         Lyophilized                               0.5, 1.0, 2.5 and 5.0 g                                  IV      Albumin, glucose and Sodium Chloride                                                      N/D       Greencross Plasma Derivatives - Korea
  Imunoglobulina humana Normal® (Blausiegel)                          Lyophilized                               0.6,3.0, 6.0 and 9.0 g                                   IM      Glycine, sodium chloride and sucrose                                                      No        Finnish Red Cross, Helsinki - Finland
  Imunoglobulina humana Normal® (Blausiegel)                          Lyophilized                               0.6,3.0, 6.0 and 9.0 g                                   IM      Glycine, sodium chloride and sucrose                                                      No        Finnish Red Cross, Helsinki - Finland
  Keyven ® (Macrofarma Quimica e Farmaceutica Industrial)             Injectable solution                       50 mg/mL flasks with 20, 50, 100 and 200 mL              IV      N/D                                                                                       N/D       Kedrion SPA, Italy; Hardis SPA, Italy
  Kiovig ® (Baxter)                                                   Injectable solution                       1,2.5, 5, 10 and 20g                                     IV      Glycine                                                                                   No        Baxter - Europe and North America
  Pentaglobin® (Marcos Pedrilson Produtos Hospitalares ltda)          Injectable solution                       Ampoules: 10 and 20 mL, Flasks: 50 and 100 mL            IV      Glucose 27.5 mg; Sodium Chloride: 78 mmol                                                 N/D       Biotest Pharma GmbH, Germany
  Sandoglobulina® (Meizler Comercio Internacional S/A)                Lyophilized                               1.0,3.0, 6.0 and 12.0 g                                  IV      Sucrose: 1.67 g/g IgG, Sodium Chloride: 0.02 g/g protein                                  N/D       ZLB - Bioplasma AG, Switzerland
  Sandoglobulina ® (CSL Behring Comercio de Produtos Farmaceuticos)   Lyophilized                               1, 3, 6, and 12 g                                        IV      Sucrose, Sodium Chloride                                                                  No        CSL Behring AG - Switzerland; CSL Behring LLC-United States
  Vigam®-Liquid (Meizler Comercio Internacional S/A)                  Injectable solution                       1, 2.5 and 5 g                                           IV      Albumin: 20mg, Sucrose: 24 mg, Glycine: 5 mg, In acetate: 3 mg, n-octanoate, Na: 0.5 mg   N/D       BPL - Bio Products Laboratory Dagger Lane, Elstree -United Kingdom
  Tegeline ® (LFB-Hemoderivados e Biotecnologia)                      Lyophilized                               0.5, 2.5, 5 and 10 g                                     IV      N/D                                                                                       N/D       LFB-Biomedicaments-France
  Venimmuna N ® (CSL Behring)                                         Lyophilized                               50 mg/mL with diluent flasks of 10, 50, 100 and 200 mL   IV      Water for injection                                                                       N/D       ZLB Behring GMBH-Germany

IV= intravenous, IM=intramuscular, N/D=not declared

In Brazil, the quality parameters of Ig for therapeutic use were defined by the National Agency of Sanitary Surveillance (ANVISA) in 2000 and are explained in [Table 3](#T3){ref-type="table"}.

###### 

Key features of the quality of Ig^([@R25])^

  Parameter analyzed                                                          Expected result
  --------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Visual inspection                                                           \- Preparation lyophilized: powder or solid mass crispy white or slightly yellowish - Solution: color between pale yellow and colorless, free of particles
  Volume                                                                      Should range up to 5% of declared on the label
  pH                                                                          \- Intramuscular: 6.4-7.2 - Intravenous: 4-7.4
  Protein concentration                                                       \- Intramuscular: 100-180 g/L - Intravenous: at least 30 g/L
  Electrophoretic purity                                                      \- Intramuscular: gamma globulin corresponds to 90% of the total protein sample - Intravenous: gamma globulin is 95% of the total protein present in the sample
  Determination of polymers and aggregates                                    \- Intramuscular: less than 10% of polymer aggregates - Intravenous: less than 3% of polymer aggregates
  Proof of Identity                                                           Reactivity only with anti-human serum
  Determination of antibodies against surface antigens of hepatitis B virus   More than 0.5 IU/g should be detected
  Test of normal Ig power                                                     \- Intramuscular: at least 10 times more potent than the initial mixture - Intravenous: at least 3 times more potent than the original mixture
  Determination of pre-kallikrein activator                                   Activity less than 35 IU/mL (solution of 30g/L)
  Determination of anti-complementary activity                                Complement consumption below 50% (1 mg of CH50 per mg of Ig)
  Determination of hemagglutinin anti-A and anti-B                            No agglutination when dilution equal to 1:64
  Osmolality                                                                  Above 240 mosmol/kg

Injectable Ig solution should be stored refrigerated between 4-8 degrees and has a shelf life of two to three years. Lyophilized Ig should be stored at room temperature (up to 25 degrees) and has a shelf life of up to five years.^([@R25])^

Recently, there has been a tendency to produce Ig solutions with higher protein concentrations, such as 100 mg/mL solutions (10%) and use a low pH that favors product stability (pH = 4.3 to 5.0). The increase in IgG concentration (from 5 to 10%) reduces the time of infusion, which is very important for patients with primary immunodeficiency who receive blood products every 21-28 days.^([@R26])^

Dosage and administration of immunoglobulins
============================================

There are several recommended Ig dosages according to clinical indication. The replacement dose of Ig in immunodeficiency must be individualized for each patient.^([@R5])^ For other situations, the dose commonly used in adults is 2 g/kg, which can be split over five days of infusion (0.4 g/kg/day) or over two days of infusion (1 g/kg/day). The infusion over two days is particularly indicated in patients with acute and severe conditions.

The usual speed of Ig infusion varies from 4 mL to 8 mL/kg/h depending on formulation (whether 5% or 10%) and patient tolerability.At the beginning of infusion, however, the speed should be slower at around 0.4 to 0.6 mL/kg/h that is the equivalent to 0.01 mL/kg/min.^([@R6])^ It is recommended to accompany the first 20 minutes of infusion of this blood product.

Ig is usually infused intravenously either in peripheral veins or central catheters. Subcutaneous administration has been used in patients without venous access and/or home infusions with the help of specially designed infuser. In exceptional circumstances, Ig can be administered orally or intrathecally.^([@R6])^

Conclusions
===========

Ig is the most commonly used blood product in clinical practice. Over the years, there has been considerable progress in its production from the processing of plasma, which guarantees better product safety, especially considering the reduction in viral transmission.

Despite the various formulations of Ig available on the market, all of them must follow quality parameters spelled out by Brazilian legislation, which seeks to ensure the quality of this blood product.

The mechanisms of action of Ig are multiple and go far beyond simply blocking Fc receptors of phagocytes. It is believed that many mechanisms are yet to be clarified and will certainly contribute to better clinical indications of this blood product.
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